Literature DB >> 24375298

Optimizing the outcome of vascular intervention for Takayasu arteritis.

A H Perera1, T Youngstein, R G J Gibbs, J E Jackson, J H Wolfe, J C Mason.   

Abstract

BACKGROUND: Takayasu arteritis (TA) predisposes to the development of arterial stenoses and aneurysms, and is associated with considerable morbidity and mortality amongst young patients. The aims of this study were to analyse indications and outcomes of surgical intervention, and to assess the potential benefits of immunosuppression and the use of perioperative imaging.
METHODS: This was a retrospective review of patients with TA referred between 2001 and 2012.
RESULTS: A series of 97 patients with TA, seen at a single tertiary centre, is reported. Immunosuppression was required in 87 patients (90 per cent). Thirty-seven (38 per cent) underwent 64 procedures: 27 patients underwent 33 open surgical procedures and 20 patients had 31 endovascular procedures. After a median follow-up of 6 years, the overall success rate was 79 per cent for open surgery (mean graft patency 9.4 years) and 52 per cent for endovascular procedures (P = 0.035). Procedural failure was significantly reduced in patients receiving preoperative immunosuppression, and particularly endovascular procedures (P = 0.001). In addition to clinical examination and measurement of acute-phase reactants, combination non-invasive imaging including Doppler ultrasonography, [18F]fluorodeoxyglucose combined positron emission and computed tomography (CT), magnetic resonance angiography and CT angiography was used to identify arterial lesions, establish the diagnosis and monitor treatment outcomes.
CONCLUSION: Outcomes of vascular intervention in TA may be improved by detailed preoperative assessment including measurement of disease activity, and by ensuring optimal immunomodulatory therapy before and after the procedure.
© 2013 BJS Society Ltd. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24375298     DOI: 10.1002/bjs.9372

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

Review 1.  Recent advances in Takayasu's arteritis.

Authors:  Fatma Alibaz-Öner; Sibel Zehra Aydın; Haner Direskeneli
Journal:  Eur J Rheumatol       Date:  2015-03-01

2.  A case of a patient with Takayasu arteritis treated with left subclavian artery stent implantation.

Authors:  Young Kyun Choi; Young Ok Jung; Han Myun Kim; Min-Kyung Kang
Journal:  J Cardiol Cases       Date:  2015-07-08

3.  Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients.

Authors:  Nilton Salles Rosa Neto; Samuel Katsuyuki Shinjo; Maurício Levy-Neto; Rosa Maria Rodrigues Pereira
Journal:  Rheumatol Int       Date:  2017-02-21       Impact factor: 2.631

Review 4.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

5.  New endovascular techniques for treatment of life-threatening Takayasu arteritis.

Authors:  Marek Kazibudzki; Łukasz Tekieli; Mariusz Trystuła; Piotr Paluszek; Zbigniew Moczulski; Piotr Pieniążek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-05-11       Impact factor: 1.426

Review 6.  Advances in Takayasu arteritis: An Asia Pacific perspective.

Authors:  Debashish Danda; Prathyusha Manikuppam; Xinping Tian; Masayoshi Harigai
Journal:  Front Med (Lausanne)       Date:  2022-08-15

7.  Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.

Authors:  Ana F Águeda; Sara Monti; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Bhaskar Dasgupta; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.